Literature DB >> 21033623

Imbalance of VEGF family serum levels and receptors in patients with inflammatory bowel disease.

O Kemik1, Sarbay A Kemik, S Purýsa, S Tuzun.   

Abstract

The aim of this study was to analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF)-A, -C, and -D, and their receptors, VEGFR-1 and -2 in inflammatory bowel disease (IBD). The serum levels of VEGF family members were measured in 80 control subjects and 200 patients with inflammatory bowel disease using an enzyme linked immunosorbent assay (ELISA). These measurements were evaluated with regard to the levels of inflammatory markers, such as C reactive protein (CRP) and serum amyloid A (SAA) and the clinical characteristics of patients, so that potential correlations could be recorded. A correlation between VEGF and their receptors serum levels is present in IBD patients. These new findings open the question on the potential role of VEGF and their receptors in IBD (Tab. 2, Ref. 9).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21033623

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  3 in total

1.  Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery.

Authors:  Qizhi Wang; Xiangguo Tian; Chunqing Zhang; Qiangxiu Wang
Journal:  Med Oncol       Date:  2011-11-19       Impact factor: 3.064

2.  Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing.

Authors:  Sundeep G Keswani; Swathi Balaji; Louis D Le; Alice Leung; Jignesh K Parvadia; Jason Frischer; Seiichi Yamano; Norton Taichman; Timothy M Crombleholme
Journal:  Wound Repair Regen       Date:  2013-06-11       Impact factor: 3.617

3.  Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer.

Authors:  Hiroaki Kobayashi; Takeo Kosaka; Shuji Mikami; Yasumasa Miyazaki; Kazuhiro Matsumoto; Eiji Kikuchi; Akira Miyajima; Kaori Kameyama; Yasufumi Sato; Mototsugu Oya
Journal:  Oncotarget       Date:  2017-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.